CFCX yields 12.54% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 5
Combined, CFCX + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CFCX + ABBV for your $10,000?
Centric Financial Corporation operates as the holding company for Centric Bank that offers various banking products and services. It provides checking accounts, certificates of deposit (CD), individual retirement accounts, savings and money market accounts, and health savings accounts; and CD account registry services. The company also offers personal and auto loans, business loans and lines, home equity loans and lines, government-guaranteed loans, commercial real estate loans, lines and letters of credit, and commercial term loans, as well as financing for doctors and professional practices; credit cards; cash management services; residential mortgages; and online and mobile banking services. In addition, it provides leasing services for business equipment; and other banking services, such as telephone banking, debit cards, fraud protection, ATM cards, bounce protection, checking navigator, notary, and safe deposit boxes. The company serves businesses and individuals, as well as healthcare providers, professional practitioners, government and municipalities, and nonprofit organizations. It offers its services through seven full-service offices in Dauphin, Cumberland, Lancaster, Bucks, and Chester Counties; and a loan production office in Chester county, as well as online banking channels. Centric Financial Corporation was founded in 2007 and is headquartered in Harrisburg, Pennsylvania.
Full CFCX Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.